NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Leukodystrophy Overview

, MD, , MD, , MD, , MPH, MGC, CGC, and , MD, PhD.

Author Information

Initial Posting: .

Summary

Clinical characteristics.

Leukodystrophies are heritable myelin disorders affecting the white matter of the central nervous system with or without peripheral nervous system myelin involvement. Involvement of the white matter tracts almost universally leads to motor involvement that manifests as hypotonia in early childhood and progresses to spasticity over time. This may lead to variable motor impairment, from mild spastic diplegia to severe spastic quadriplegia that limits purposeful movement. In addition, motor dysfunction is likely to significantly impair vital functions including swallowing, chewing, and (in some cases) respiration. Other findings that vary by disorder include extrapyramidal movement disorders (e.g., dystonia and/or dyskinesias), ataxia, seizures, and delay in cognitive development or change in cognitive function over time.

Diagnosis/testing.

Establishing the specific leukodystrophy present in a given individual usually involves:

  • Obtaining a medical history and detailed family history
  • Performing a physical examination and neurologic examination
  • Review of brain MRI findings:
    • T2-weighted hyperintensity in the white matter is the MRI finding required for diagnosis of a leukodystrophy.
    • T1-weighted signal may be variable: iso- or hyperintense T1-weighted signal is consistent with a hypomyelinating leukodystrophy; hypointense T1-weighted signal is consistent with a demyelinating leukodystrophy.
  • Performing specialized laboratory testing, often including molecular genetic testing (either stepwise single gene testing or use of a multigene panel targeted to the leukodystrophies).

Genetic counseling.

Leukodystrophies with an identified genetic cause may be inherited in an autosomal dominant manner, an autosomal recessive manner, or an X-linked recessive manner. Genetic counseling regarding risk to family members depends on accurate diagnosis, determination of the mode of inheritance in each family, and results of molecular genetic testing. Prenatal testing for pregnancies at increased risk is possible for some types of leukodystrophy if the pathogenic variant(s) in the family are known. Many leukodystrophies are still without an identified genetic cause; once a genetic cause is identified, other inheritance patterns may emerge.

Management.

Treatment of manifestations: Treatment is symptomatic and ideally occurs in a multidisciplinary setting by specialists experienced in the care of persons with a leukodystrophy. Pharmacologic agents are used to manage muscle tone and block neuronal signaling to muscle (chemodenervation). Intensive physical therapy is used to improve mobility and function. Pharmacologic treatment of dystonia and dyskinesias may result in significant functional improvement. Treatment of ataxia, seizures, and cognitive issues is provided in the usual manner, depending on the needs of the individual.

Prevention of primary manifestations: In a few leukodystrophies primary disease manifestations can be prevented by hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation (BMT) early in the disease course.

Surveillance: Routine assessment of growth and nutritional status; physical examination and/or serial x-rays of the hips and spine to monitor for orthopedic complications; and routine history re signs and symptoms of seizures.

Agents/circumstances to avoid: Mild head injuries and infection as these may exacerbate disease manifestations.

Evaluation of relatives at risk: When primary prevention of a leukodystrophy is possible (e.g., by HSCT or BMT), it is appropriate to offer testing to asymptomatic at risk relatives who would benefit from early diagnosis and consideration of early treatment.

Definition of Leukodystrophy

The term leukodystrophy, as well as associated terms such as dysmyelination, demyelination, and leukoencephalopathy, are applied to a broad group of disorders.

In this GeneReview chapter, the following definition is used: Leukodystrophies are heritable myelin disorders affecting the white matter of the central nervous system with or without peripheral nervous system myelin involvement.

Leukodystrophies share the following findings:

  • Abnormalities of the glial cell or myelin sheath, such that neuropathology – when known – is characterized primarily by involvement of oligodendrocytes, astrocytes, and other non-neuronal cell types. Of note, in many leukodystrophies the underlying disease mechanism is unknown.
  • MRI findings (see Figure 1)
    • T2-weighted hyperintensity in the white matter must be present.
    • T1-weighted signal may be variable: iso- or hyperintense T1-weighted signal is consistent with a hypomyelinating leukodystrophy; hypointense T1-weighted signal is consistent with a demyelinating leukodystrophy.
Figure 1. . Hypomyelinating leukodystrophy has T2-weighted hyperintensity (↑) and T1-weighted iso- (→) or hyperintensity (↑) of affected white matter.

Figure 1.

Hypomyelinating leukodystrophy has T2-weighted hyperintensity (↑) and T1-weighted iso- (→) or hyperintensity (↑) of affected white matter. Demyelinating leukodystrophy has T2-weighted hyperintensity (↑) and T1-weighted (more...)

Clinical Manifestations of Leukodystrophies

A number of leukodystrophies that meet the definition used in this GeneReview chapter are listed in Table 1.

Involvement of the white matter tracts almost universally leads to motor involvement that manifests as hypotonia in early childhood and progresses to spasticity over time. This may lead to variable motor impairment, from mild spastic diplegia to severe spastic quadriplegia that limits purposeful movement. In addition, motor dysfunction is likely to significantly impair vital functions including swallowing, chewing and (in some cases) respiration. Spasticity may result in orthopedic complications such as scoliosis and large joint luxation.

Significant pyramidal dysfunction (i.e., spasticity) may sometimes mask or overshadow the presence of extrapyramidal movement disorders such as dystonia and/or dyskinesias. For example, in MCT8-specific thyroid hormone cell transporter deficiency dystonia is a prominent finding.

Ataxia is a predominant finding in some leukodystrophies and can be disabling; for example, childhood ataxia with central nervous system hypomyelination/vanishing white matter (CACH/VWM) and hypomyelination with hypogonadotropic hypogonadism and hypodontia (4H syndrome).

Seizures are an often late manifestation of leukodystrophies, with the exception of rare leukodystrophies (e.g., Alexander disease) in which they are often a presenting feature.

Delay in cognitive development or change in cognitive function over time, while far less pronounced than motor dysfunction, can be common in the child or adult with leukodystrophy. Because progressive loss of cognitive function is slow in the majority of leukodystrophies, dementia is not an early feature.

Prevalence of Leukodystrophies

Epidemiologic data on the frequency of leukodystrophies overall are limited [Heim et al 1997, Bonkowsky et al 2010]. Furthermore, it is difficult to infer from these studies with any certainty the relative frequency of specific leukodystrophies.

Better information on prevalence is available for leukodystrophies that are seen regularly in specialized clinics and in general child neurology practices; these include Alexander disease [van der Knaap et al 1999], X-linked adrenoleukodystrophy [Bezman et al 2001] and metachromatic leukodystrophy.

As disorders such as certain adult-onset-only leukodystrophies and hypomyelinating leukodystrophies become better defined, the heterogeneity of the inherited white matter disorders is increasingly recognized.

It is important to note that in approximately 50% of individuals with a white matter disorder the specific etiology is unknown because of the heterogeneity and complexity of these disorders [Schiffmann & van der Knaap 2009].

Differential Diagnosis of Leukodystrophies

Hereditable disorders with significant white matter involvement that are not leukodystrophies are listed in Table 2 (pdf); they include the following:

  • Inherited vasculopathies that can result in white matter signal abnormalities, including inherited abnormalities of the vessel wall, such as CADASIL and COL4A1 and COL4A2-related disorders, which can give rise to multifocal white matter abnormalities. In end-stage disease, confluent signal abnormalities in the periventricular and deep white matter may be seen, typically with multifocal abnormalities in central gray matter structures and brain stem. Because these are not primary glial cell disorders, they are not considered to be leukodystrophies.
  • CNS diseases with primary involvement of neurons in the cerebral cortex or other gray matter structures (in which brain MRI also reveals significant white matter abnormalities). Typical findings are significant encephalopathy and seizures.
    • The infantile variants of disorders like GM1 gangliosidosis, GM2 gangliosidosis, and neuronal ceroid-lipofuscinosis may have significant white matter abnormalities because the disease, which is primarily neuronal, also disrupts the normal process of myelination. Later-onset variants of these disorders eventually affect the cerebral white matter; mild signal abnormalities are related to Wallerian degeneration with loss of axons and myelin.
    • In other disorders, such as MCT8-specific thyroid hormone cell transporter deficiency, myelination can be extremely delayed but progress over time to become almost complete.
  • Inborn errors of metabolism with significant secondary white matter abnormalities, such as organic acidemias, disorders of amino acid metabolism and many others. See Table 2 (pdf).
  • Disorders that affect both white and gray matter. Examples in which both white matter injury and gray matter lesions are observed include mitochondrial disorders such as MELAS (mitochondrial encephalopathy with lactic acidosis and seizures), POLG-related disorders, and familial hemophagocytic lymphohistiocytosis.

Other disorders with significant white matter involvement include the following:

  • Acquired CNS myelin disorders that result in demyelination, such as multiple sclerosis and those of infectious, post-infectious, and autoimmune etiology. Although not heritable in a Mendelian fashion, some of these disorders may have multifactorial etiologies that include a genetic predisposition.
  • Disorders such as acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica typically differ from heritable white matter disorders by their abrupt onset and multiphasic presentations. Brain MRI abnormalities are also more likely to be multifocal and patchy [Schiffmann & van der Knaap 2009], with variation or even improvement over time and with treatment.
  • Toxic injuries of the myelin, such as those seen in heroin abuse or methotrexate-related toxicity
  • Central nervous system injury, particularly in the perinatal period, which can result in significant white matter signal abnormalities that are typically irregular, and may result in loss of white matter volume
  • Non-genetic vascular insults

Evaluation Strategy for an Individual with a Leukodystrophy

Once a leukodystrophy is considered in an individual, the following approach can be used to determine the specific leukodystrophy to aid in discussions of prognosis and genetic counseling.

Establishing the specific leukodystrophy (Table 1) present in a given individual usually involves obtaining a medical history and detailed family history; performing a physical examination and neurologic examination; review of brain MRI findings; and specialized laboratory testing, often including molecular genetic testing.

Note: Adherence to the diagnostic approach discussed in this section notwithstanding, a specific diagnosis cannot be established in a clinical (i.e., not research) setting in a significant number of individuals with a leukodystrophy [van der Knaap et al 1999, Schiffmann & van der Knaap 2009].

Medical History

A history of certain clinical features may be helpful in identifying a specific leukodystrophy; however, in the majority of cases, only nonspecific loss of function (primarily motor) occurs and medical history alone does not provide insight into a specific diagnosis.

In the hypomyelinating leukodystrophies helpful diagnostic clues may, for example, be the following:

In the demyelinating leukodystrophies helpful diagnostic clues may, for example, be the following:

Family History

A detailed three-generation family history focusing on individuals with hypotonia, spasticity, dystonia, seizures, ataxia, and/or delay in cognitive development or change in cognitive function over time.

  • Because most leukodystrophies are autosomal recessive, special attention to parental consanguinity and medical problems in sibs is warranted.
  • Evaluation of relatives and/or review of their medical records may be needed.

Physical Examination and Neurologic Examination

In most instances physical findings do not suggest a specific diagnosis; however, certain findings may direct the reader to further explore specific underlying etiologies:

Brain MRI Findings

Step 1

Establish whether the pattern of brain MRI abnormalities is consistent with a hypomyelinating leukodystrophy or a demyelinating leukodystrophy (Figure 1) [van der Knaap et al 1999, van der Knaap & Valk 2005, Schiffmann & van der Knaap 2009].

Step 2

Within the hypomyelinating and demyelinating leukodystrophies, determine if patterns of involvement suggest specific diagnoses.

Hypomyelinating leukodystrophy. Note specific patterns on neuroimaging that include the following (Figure 2):

Figure 2.

Figure 2.

Hypomyelinating leukodystrophy – patterns on MRI A→B. Improvement of myelination over time in MCT8-specific thyroid hormone cell transporter deficiency seen in a male with documented SLC16A2 (MCT8) pathogenic variants at age two years (more...)

Demyelinating leukodystrophy

  • Identify the region in which white matter abnormalities predominate.
  • Distinguish confluent from multifocal lesions (Figure 3):
    • Confluent white matter lesions are extensive white matter abnormalities in significant portions of the brain, often affecting specific regions or tracts, although not necessarily perfectly symmetrically.
    • Multifocal white matter lesions are more discrete, often asymmetric and involving a limited area. Multifocal abnormalities have a specific differential diagnosis.
Figure 3. . Confluent white matter lesions are extensive white matter abnormalities in significant portions of the brain, often affecting specific regions or tracts, although not necessarily perfectly symmetrically.

Figure 3.

Confluent white matter lesions are extensive white matter abnormalities in significant portions of the brain, often affecting specific regions or tracts, although not necessarily perfectly symmetrically. Multifocal white matter lesions are more discrete, (more...)

Specific patterns on neuroimaging in confluent disorders include (Figure 4):

Figure 4.

Figure 4.

Demyelinating leukodystrophy – patterns on MRI

Diagnostic algorithm. For algorithms based on MRI findings, see Figure 5 (demyelinating and other conditions) and Figure 6 (hypomyelinating conditions) [Schiffmann & van der Knaap 2009].

Figure 5.

Figure 5.

Algorithm Part 1: Demyelinating and other conditions Adapted from Schiffmann & van der Knaap [2009]

Figure 6.

Figure 6.

Algorithm Part 2: Hypomyelinating conditions Adapted from Schiffmann & van der Knaap [2009]

Step 3

Look for the following associated features which, in addition to the pattern of findings on brain MRI, can assist in recognition of a specific leukodystrophy:

Figure 7.

Figure 7.

Features associated with specific leukodystrophies

Specialized Laboratory Testing (including Molecular Genetic Testing)

If the findings on brain MRI are consistent with a specific leukodystrophy, consider biochemical or molecular genetic testing for that disorder (Table 1). Note: Molecular genetic testing may be performed either as single-gene testing in a stepwise fashion based on the information gained during the evaluation or, if available, as a multigene panel. For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

Table 1.

Leukodystrophies Meeting Strict Diagnostic Criteria

Name of DisorderMode of InheritanceGene 1Biochemical Testing / Other
18q deletion syndromeMost often de novo deletion; may be inheritedChromosome analysis for 18q microdeletion involving MBP
Adult polyglucosan body disease (APBD)ARGBE1Histopathologic examination of muscle, nerve, axillary skin: pathologic polyglucosan accumulation
Aicardi-Goutières syndrome (AGS)Usually AR; may be ADTREX1
RNASEH2A
RNASEH2B
RNASEH2C
SAMHD1
ADAR
CSF analysis: lymphocytosis, ↑ interferon-α, ↑ pterins
Alexander diseaseADGFAP
AD adult-onset leukodystrophy (ADLD)ADLMNB1
Cerebroretinal microangiopathy w/calcifications & cysts (CRMCC) 2Likely ARClinical & neuroradiologic features
Canavan diseaseARASPAIn urine, plasma, CSF, & amniotic fluid: ↑ N-acetylaspartic acid in urine;
In skin fibroblasts: deficient aspartoacylase enzyme activity
Cerebrotendinous xanthomatosis (CTX)ARCYP27A1In plasma & CSF: ↑ cholestanol concentration, ↓ chenodeoxycholic acid;
In bile, urine, plasma: ↑ concentration bile alcohols & glyconjugates;
In fibroblasts, liver, leukocytes: ↓ sterol 27-hydroxylase activity
Childhood ataxia w/CNS hypomyelination / vanishing white matter (CACH/VWM)AREIF2B1-5
Free sialic acid storage disorders 3ARSLC17A5In urine, fibroblast, lysosomes: ↑ free sialic acid
FucosidosisARFUCA1On urinary oligosaccharide assay: ↑ fucose-containing glycoconjugates;
In leukocytes or fibroblasts: deficient α-fucosidase activity
Hypomyelination w/atrophy of the basal ganglia & cerebellum (H-ABC)Likely ADTUBB4AClinical & neuroradiologic features
Hypomyelination and congenital cataract (HCC)ARFAM126A
Krabbe diseaseARGALC
See footnote 4
In leukocytes or fibroblasts: deficient galactocerebrosidase activity
L-2-hydroxyglutaric aciduriaARL2HGDHIn plasma, urine, CSF: ↑ concentration of L-2-hydroxyglutaric acid (and lysine)
Leukoencephalopathy w/brain stem & spinal cord involvement & lactate elevation (LBSL)ARDARS2
Leukoencephalopathy w/thalamus and brain stem involvement & lactate elevation (LTBL)AREARS2
Megalencephalic leukodystrophy w/subcortical cysts (MLC)ARMLC1
HEPACAM (MLC2)
Metachromatic leukodystrophy (MLD)ARARSAIn leukocytes, fibroblasts: ↓ arylsulfatase A activity;
In urine: ↑ sulfatides
PSAP-related MLD 5PSAPIn leukocytes, fibroblasts: normal arylsulfatase A activity;
In urine: ↑ sulfatides
Multiple sulfatase deficiency (MSD)SUMF1↓ activity of other sulfatases;
In urine: ↑ mucopolisaccharides, ↑ urinary sulfatides
Hereditary diffuse leukoencephalopathy w/spheroids (HDLS) 6ADCSF1R
Oculodentodigital dysplasia (ODDD)Usually AD; may be ARGJA1
Pelizaeus-Merzbacher disease (PMD)XLPLP1
Pelizaeus-Merzbacher-like disease 1 (PMLD1)ARGJC2
Zellweger spectrum disorder (PBD, ZSD) 7ARPEX genesPlasma VLCFA, phytanic & pristanic acid, plasma & urine concentration of pipecolic acid & bile acids aid to distinguish different forms of peroxisomal disorders
Pol III-related leukodystrophies 8ARPOLR3A
POLR3B
RNAse T2-deficient leukoencephalopathyARRNASET2
Single-enzyme deficiencies of peroxisomal fatty acid beta oxidation 9ARDibifunctional protein deficiency: HSD17B4Plasma VLCFA, phytanic & pristanic acid, plasma & urine concentration of pipecolic acid & bile acids aid to distinguish different forms of peroxisomal disorders
Peroxisomal acyl-CoA-oxidase deficiency: ACOX1
SCPx deficiency: SCP2
Sjögren-Larsson syndromeARALDH3A2In urine: abnormal metabolites of leukotriene B4;
In cultured skin fibroblasts, leukocytes: deficiency of fatty aldehyde dehydrogenase activity (FALDH) and/or of fatty alcohol:NAD oxidoreductase (FAO)
SOX10-associated disordersADSOX10
X-linked adrenoleukodystrophy (X-ALD)XLABCD1On plasma VLCFA assay: C26:0, ↑ ratio of C24:0 to C22:0, ↑ ratio of C26:0 to C22:0

VLCFA = very long-chain fatty acid

Disorders listed in alphabetic order; naming as per GeneReviews

1.

Genetic testing is available for many of these genes.

2.

This disorder now appears to be distinct from Coats plus caused by pathogenic variants in CTC1, encoding conserved telomere maintenance component 1.

3.

Includes Salla disease; infantile sialic acid storage disease, intermediate form

4.

Defects in PSAP causing a deficiency in the activator protein of SapA-d essential for the action of GALC have been reported.

5.

Pathogenic variants in PSAP result in deficiency in SapB-d, an activator protein essential for ARSA activity.

6.

Also known as adult-onset leukodystrophy w/ neuroaxonal spheroids & pigmented glia; may include hereditary diffuse; pigmentary type of orthochromatic leukodystrophy w/pigmented glia (POLD)

7.

Includes neonatal adrenoleukodystrophy; infantile Refsum disease

8.

Includes hypomyelination, hypodontia, hypogonadotropic hypogonadism (4H syndrome); ataxia, delayed dentition, and hypomyelination (ADDH); tremor-ataxia with central hypomyelination (TACH); leukodystrophy with oligodontia (LO); and hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum (HCAHC).

9.

Includes D-bifunctional protein (DBP) deficiency; sterol carrier protein-2 (SCPx) deficiency; peroxisomal acyl-CoA-oxidase deficiency

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Leukodystrophies with an identified genetic cause may be inherited in an autosomal dominant manner, an autosomal recessive manner, or an X-linked recessive manner; other inheritance patterns may be identified as more genetic causes of leukodystrophy are discovered.

If a proband has a specific syndrome associated with a leukodystrophy, counseling for that condition is indicated.

Risk to Family Members – Autosomal Dominant Inheritance

Parents of a proband

Sibs of a proband

  • The risk to sibs depends on the genetic status of the proband's parents.
  • If one of the proband's parents has a mutated allele, the risk to the sibs of inheriting the mutated allele is 50%.

Offspring of a proband. Individuals with autosomal dominant leukodystrophy have a 50% chance of transmitting the mutated allele to each child.

Risk to Family Members – Autosomal Recessive Inheritance

Parents of a proband

  • The parents are obligate heterozygotes and therefore carry a single copy of a pathogenic variant.
  • Heterozygotes are asymptomatic.

Sibs of a proband

  • At conception, each sib of a proband has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
  • Once an at-risk sib is known to be unaffected, the chance of his/her being a carrier is 2/3.

Offspring of a proband. All offspring are obligate carriers.

Risk to Family Members – X-Linked Inheritance

Parents of a proband

  • The father of an affected male will not have the disease nor will he be a carrier of the pathogenic variant.
  • Women who have an affected son and another affected male relative are obligate heterozygotes. These females may be affected, sometimes with only certain features of the disease, or with milder symptoms. Note: If a woman has more than one affected child and no other affected relatives and if the pathogenic variant cannot be detected in her leukocyte DNA, she has germline mosaicism. Rarely, the unaffected father of an affected female may have germline mosaicism.
  • A mother of an affected female who has a pathogenic variant may have favorably skewed X-chromosome inactivation that results in her being unaffected or mildly affected.
  • An individual who is the only affected family member (i.e., a simplex case) may have a de novo pathogenic variant.

Sibs of a proband. The risk to sib depends on the carrier status of the mother:

  • If the mother of the proband has a pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Male sibs who inherit the variant will be affected; female sibs who inherit the variant will be carriers and will usually not be affected.
  • If the proband represents a simplex case (i.e., a single occurrence in a family) and if the pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal germline mosaicism.

Offspring of a proband

  • Daughters of an affected male will be obligate carriers and may or may not be affected; none of his sons will be affected.
  • Each child of an affected female has a 50% chance of inheriting the pathogenic variant.
  • Because of possible skewing of X-chromosome inactivation, variable phenotypes in females are possible.

Other family members of a proband. The risk to other family members depends on the genetic status of the proband’s parents.

Related Genetic Counseling Issues

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing and Preimplantation Genetic Diagnosis

Once the pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for leukodystrophy are possible.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • Myelin Disorders Bioregistry Project
    Email: myelindisorders@cnmc.org

Management

Treatment of Manifestations

Although the underlying mechanisms of leukodystrophies are diverse, many manifestations are similar across this group of disorders. In the great majority of cases, primary treatment is not possible, but management of symptoms can improve the comfort and care of individuals with these complex disorders.

Ideally, the child or adult with a leukodystrophy is managed in a multidisciplinary setting by providers experienced in the care of persons with a leukodystrophy.

Spasticity. Pharmacologic agents are used to manage muscle tone and block neuronal signaling to muscle (chemodenervaton). Intensive physical therapy is used to improve mobility and function.

Extrapyramidal manifestations. Dystonia and dyskinesias may cause significant disability; pharmacologic treatment may result in significant functional improvement.

Ataxia. No specific treatment of ataxia exists, although rehabilitative measures can be of great assistance.

Seizures. Seizures should be treated with typical anticonvulsants and are rarely refractory, except on occasion at the end of life.

Cognitive developmental delay/encephalopathy. It is important to advocate for persons with a leukodystrophy in school or at work to avoid limitations related to their motor disabilities. Augmentative communication may be used to address speech deficits. Accommodations for cognitive delays and fine motor disabilities should be used as needed.

Orthopedic. Attention should be given to the prevention and treatment of orthopedic problems, such as hip dislocation and scoliosis.

Feeding. Swallowing dysfunction and pulmonary problems resulting from the increased risk of aspiration are common as the disease progresses. Decreased nutritional intake and failure to thrive may also occur. The decision to place a gastrostomy tube for nutrition is based on the overall health status of the individual, expected disease course, and family and patient wishes.

Prevention of Primary Manifestations

Primary disease manifestations can be prevented in a few of the leukodystrophies: in X-linked adrenoleukodystrophy, Krabbe disease, and metachromatic leukodystrophy, for example, hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation (BMT) may be beneficial if performed early in the disease course. Patients with these disorders should be referred to specialized centers for consideration of HSCT or BMT [Eichler et al 2009].

Surveillance

Standard surveillance includes the following:

  • Routine measurement of weight and height to assess growth and nutritional status
  • Physical examination and/or serial x-rays of the hips and spine to monitor for orthopedic complications
  • Routine history re signs and symptoms of seizures

Certain disorders require specialized surveillance, for example monitoring for the development of hydrocephalus in Alexander disease.

Agents/Circumstances to Avoid

In a number of leukodystrophies anecdotal evidence suggests episodic worsening of manifestations with mild head injuries and infection. While this has been clearly documented only for childhood ataxia with central nervous system hypomyelination/vanishing white matter, it appears prudent to avoid these triggers when possible.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

References

Literature Cited

  • Bezman L, Moser AB, Raymond GV, Rinaldo P, Watkins PA, Smith KD, Kass NE, Moser HW. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol. 2001;49:512–7. [PubMed: 11310629]
  • Bonkowsky JL, Nelson C, Kingston JL, Filloux FM, Mundorff MB, Srivastava R. The burden of inherited leukodystrophies in children. Neurology. 2010;75:718–25. [PMC free article: PMC2931652] [PubMed: 20660364]
  • Eichler F, Grodd W, Grant E, Sessa M, Biffi A, Bley A, Kohlschuetter A, Loes DJ, Kraegeloh-Mann I. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. AJNR Am J Neuroradiol. 2009;30:1893–7. [PubMed: 19797797]
  • Heim P, Claussen M, Hoffmann B, Conzelmann E, Gärtner J, Harzer K, Hunneman DH, Köhler W, Kurlemann G, Kohlschütter A. Leukodystrophy incidence in Germany. Am J Med Genet. 1997;71:475–8. [PubMed: 9286459]
  • Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology. 2009;72:750–9. [PMC free article: PMC2677542] [PubMed: 19237705]
  • van der Knaap MS, Breiter SN, Naidu S, Hart AA, Valk J. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology. 1999;213:121–33. [PubMed: 10540652]
  • van der Knaap MS, Valk J. Magnetic Resonance of Myelination and Myelin Disorders. Berlin, Germany: Springer. 2005.

Chapter Notes

Revision History

  • 6 February 2014 (me) Review posted live
  • 14 February 2012 (av) Original submission
Copyright © 1993-2018, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2018 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

Bookshelf ID: NBK184570PMID: 24501781

Views

  • PubReader
  • Print View
  • Cite this Page
  • Disable Glossary Links

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...